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The emergence of genomics in the field of clinical 
genetics
Clinical genetics
§ Focus on monogenetic diseases
§ national networks of scientists, 
clinicians, funding bodies based 
around hospitals
§ clinical genetics centres linking 
laboratory research and 
diagnosis with clinical patient 
care and counselling
§ strong orientation of research to 
clinically relevant genetic 
diseases
§ important role for patient groups 
as intermediaries
Genomics 
§ Focus on multifactorial diseases
§ large-scale consortia with 
international, multi-disciplinary 
collaboration 
§ strategic public investments and 
public-private relationships
§ use of high throughput 
technologies
§ genetic databases as platforms 
linking academic and commercial 
interests
Genomics as a new innovation regime
§ Emergence of genomics involves an epistemological and institutional
transformation of knowledge production in human genetics
§ This transformation also has implications for the ways in which science 
and society are related in genomics
§ ‘Valorisation’ as a new challenge in genomics
§ “to ensure that society and economy benefit from the 
breakthrough enabled by genomics in important fields like health, 
sustainability, enabling technologies and society” (NGI homepage)
§ Measured in quantities of dissertations, patents, start-up 
companies, industrial matching  
§ Narrow economic definition leads to discrimination of particular research 
fields (eg. does not appreciate contribution to new diagnostic criteria)
The multi actor world of innovation
Industry
Science
Clinic
Public policy
Some useful concepts
§ Innovation regime refers to rules, procedures, and heuristics that guide
activities and interactions in networks of research and development
§ Resource driven regimes characterized by the exploration of multiple possible
paths
§ Technological regimes characterized by actor’s beliefs about ‘not yet
exploited opportunities’ along a specific path
§ Socio-technical paths refers to the (emerging) alignment between
activities of actors at different poles (science, industry, clinic)
à Valorization as knowledge production and uptake along paths towards 
clinical applications
The multi actor world of innovation
Industry
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Clinic
Public policy
Identity and roles of actors? 
Path dynamics?
Regime characteristics?
Implications for valorization? 
Two case studies
§ Duchenne Muscular Dystrophy
§ Major object of research in the clinical genetics regime (Nelis, 1998): 
monogenetic disease, strong patient involvement
§ Illustrates evolution of clinical genetics regime (e.g. current focus on
therapeutic interventions w/ commercial actors) 
§ Alzheimer’s disease
§ Typical genomics regime: multifactorial disease, use of large biobanks, 
association studies as emerging paradigm
§ Emerging regime: merging of different activities (epidemiological and 
genetic research) and new institutional forms (genetic epidemiology
departments)
Co-author map of Duchenne Muscular Dystrophy 
research
Topic = Duchenne
ISI classification = genetics & heredity
Address = Netherlands
Time: 2000-2010
Top 5 authors
>2 co-author relations
Prosensa
Exon skipping
http://www.humgen.nl/lab-aartsma-rus/
small synthetic 
antisense 
oligoribonucleotides
(AONs)
Preliminary characterization of DMD regime
§ Actors: Center for Human and Clinical Genetics (LUMC), Prosensa, 
GlaxoSmithKline, DMD patients/parents/organisations
§ Path dynamics: alignment of scientific and industrial actors via patent, spin-
off Prosensa, exon skipping technology
§ Innovation regime driven by the prospect of a new therapy
§ Implications for valorization: 
§ Science-industry relations: scientists’ commercial ties, intellectual
property, societal benefits of public funding, distribution of risks?
§ (Clinical implications: exon skipping implies patient stratificationà
solidarity in patient organisation, orphanisation vs. clinical trials?)
Preliminary characterization of Alzheimer regime
§ Actors: epidemiologists, geneticists
§ Path dynamics
§ Explorative, multiple possible paths
§ Resource driven regime: availability of abundant data and genotyping
technology, complex agenda, hypothesis generation and testing
§ Implications for valorization: 
§ If one would equally appreciate the work done in fields like Alzheimer’s
genomics, then another notion of valorization is required: one based on
the possibility of ‘path creation’ instead of ‘path dependency’
§ Management of expectations, co-creation of scenarios, interactions
between different paths (diagnosis, detection, prevention, therapy), 
knowledge uptake, long-term resource availability
To wrap up
§ Emergence of medical genomics in the field of clinical genetics
§ Clinical genetics and medical genomics are governed by different types of 
regimes, with implications for valorisation policy
§ Economic valorisation feasible in case of established technological regime 
(clinical genetics regime of Duchenne research)
§ Beyond narrow definition: Valorisation as mid- and long-term accountability
of path creation
§ Legitimacy of possible scenarios of future developments
